← Human Trials & Peer-Reviewed Studies
Vitamin D Supplementation Impacts Systemic Biomarkers of Collagen Degradation and Copper Metabolism in Patients With Keratoconus
Plain-language guide to PMID 36580321 (2022): pilot observational study of Copper (Supplement).
Key Facts
- PMID
- 36580321
- Journal
- Translational vision science & technology
- Year
- 2022
- Study type
- Observational Study
- Authors
- Lasagni Vitar RM et al. (7 authors)
- DOI
- 10.1167/tvst.11.12.16
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Copper (Supplement), published as an observational study.
To evaluate the impact of vitamin D (Vit D) supplementation on systemic biomarkers of collagen degradation, inflammation, oxidative stress, and copper metabolism in adolescent patients with keratoconus (KC).
Blood samples were collected at different time points to evaluate Vit D levels and systemic markers of collagen degradation, inflammation, oxidative stress, and copper metabolism by ELISA or RT-PCR.
Why It Was Studied
Although KC therapy currently relies exclusively on surgical procedures, Vit D supplementation may offer a non-invasive and inexpensive alternative with minimal associated side effects.
Who Took Part
PubMed indexes the participants as teenagers, young adults and adults.
Twenty patients (age range, 16-19 years) presenting KC and Vit D insufficiency (<30 ng/mL) were included.
Vit D supplementation was prescribed by their general practitioner as per the standard of care.
How the Study Was Run
The researchers set it up as a pilot study.
It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.
This was a prospective observational pilot study.
At each visit, best spectacle-corrected visual acuity (BSCVA), maximal keratometry (Kmax), and thinnest corneal thickness (TCT) were evaluated.
The primary outcome of the study was the proportion of patients with Kmax progression of less than 1 D throughout the 12-month follow-up time.
What Was Measured
The subject headings attached to it are Keratoconus, Photosensitizing Agents, Photochemotherapy, Copper, Visual Acuity, Ultraviolet Rays and Riboflavin.
What This Means in Plain Language
The paper is a pilot study of Copper (Supplement).
Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2022 (Translational vision science & technology), a journal based in United States.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.